查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018844

动物疫苗市场：2026-2032年全球市场预测（依产品类型、目标动物、疾病、给药途径及通路划分）

Animal Vaccines Market by Product, Animal Type, Disease Type, Route of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物疫苗市场价值将达到 145.8 亿美元，到 2026 年将成长到 155.3 亿美元，到 2032 年将达到 234 亿美元，复合年增长率为 6.99%。

主要市场统计数据
基准年 2025 145.8亿美元
预计年份：2026年 155.3亿美元
预测年份 2032 234亿美元
复合年增长率 (%) 6.99%

明确、有策略地组织科学进步、相关人员的压力和业务需求，以重新定义动物疫苗开发和部署的优先事项。

动物疫苗产业正处于一个关键的转折点，科学创新、疾病动态变化以及相关人员期望的不断演变在此交汇融合，重塑着生产者、兽医和政策制定者的优先事项。分子生物学和免疫学的最新进展正在加速下一代治疗方法的研发，而伴侣动物和牲畜疾病预防需求的日益增长，也使得建立强大的疫苗组合变得尤为重要。相关人员面临着日益严格的监管、动物福利方面的伦理考虑以及成本效益和分销灵活性等商业性需求的复杂博弈。贸易政策的变化、供应链的脆弱性以及对抗菌药物合理使用的日益严格的审查，进一步加剧了这些压力，所有这些都使得以疫苗主导的预防策略成为永续动物健康计划的核心。

平台创新、数位监控和不断变化的监管预期如何推动动物免疫策略进入一个准确性、可及性和韧性的新时代。

在科学突破、数位科技应用和不断变化的流行病学压力的驱动下，动物疫苗领域正经历着一场变革。 mRNA和重组技术等平台技术正从实验阶段走向应用特定领域，实现更快的抗原设计和更精准的免疫调节。同时，灭活疫苗和减毒活病毒疫苗等传统方法也在安全性和热稳定性方面进行优化，以应对长期存在的配送难题。从基因组监测到供应链分析和远端医疗数位工具，使得疫情能够更早被发现，疫苗接种宣传活动能够更快地展开，进而改变着生产商的生产週期和配送方式。

2025 年关税调整带来的连锁营运和策略影响正在重建整个动物疫苗价值链的采购、在地化生产和分销的韧性。

美国在2025年实施的关税调整对整个动物疫苗价值链产生了多方面的影响，包括筹资策略、生产经济效益和全球贸易流动。某些原材料和成品生技药品的关税上调促使製造商重新评估其供应商所在地，并加快关键生产过程的近岸外包和本地化。这些变化并非仅仅出于成本考量；它们也体现了确保疫苗生产基础——佐剂、管瓶和特殊试剂等敏感生物成分的持续供应的战略重点。因此，各组织正在优先考虑建立双重采购安排和选择新​​的契约製造合作伙伴，以减少对单一供应商的依赖。

将产品模式、动物类别、目标疾病、给药途径和分销管道进行综合细分的框架，将有助于实现差异化的开发和商业化方法。

市场区隔揭示了疫苗研发、应用和商业化的独特动态，每种情况都需要针对产品类型、目标动物、疾病类别、给药途径和通路製定量身定制的策略。按产品划分，该领域包括灭活疫苗、减毒活病毒疫苗、mRNA疫苗、重组疫苗和次单位疫苗，每种疫苗的研发週期、生产复杂性和对低温运输的依赖程度各不相同。这些差异有助于确定研发管线投资的优先顺序和生产力计画。依动物种类划分，市场涵盖伴侣动物和家畜。伴侣动物类别进一步细分为猫和狗，而家畜类别则进一步细分为牛、家禽、羊和猪。这种细分突显了家养宠物和生产动物在临床需求、给药方法和分销模式方面的显着差异，进而导致了不同的销售管道和传播策略。

区域优先事项和基础设施现状正在推动美洲、欧洲、中东和非洲以及亚太地区在政策、製造和分销策略方面出现差异。

区域趋势反映了管理体制、生产能力、疾病流行程度和分销基础设施的差异，从而影响疫苗研发者、经销商和政策制定者的策略重点。在美洲，重点在于监管协调、低温运输现代化以及官民合作关係，以满足伴侣动物和牲畜的疫苗接种需求。该地区的监管机构优先考虑疫苗的安全性和有效性，而行业相关人员则致力于透过生产自动化和与监测数据相联繫的精准疫苗接种计划来提高生产效率。区域内的跨境贸易促进了一体化生产基地的形成，但近期政策的转变正在推动供应多元化，以降低外部衝击的影响。

市场领先的公司和敏捷的创新者正在透过建立伙伴关係、确保专业製造能力和整合服务，将技术优势转化为永续的商业性地位。

动物疫苗产业的竞争格局由跨国公司、专业生物技术创新企业和提供灵活生产能力的契约製造(CMO) 组成。成熟的大型企业持续投资于产品组合多元化和生产韧性，力求在灭活疫苗和减毒活病毒疫苗等传统平台与 mRNA 和重组构建体等新兴技术之间取得平衡。新兴的专业生物技术参与企业正在开发特定适应症和平台能力，通常与 CDMO 合作以快速扩大生产规模并降低资本密集型设施建设的风险。同时，契约製造和服务供应商透过提供模组化、目标明确的生产能力，缩短产品上市时间并支援在地化工作，从而发挥日益重要的策略作用。

製造商和相关人员面临的可操作的策略挑战，包括加速创新、实现生产多元化以及加强监管和商业伙伴关係，以增强疫苗供应的韧性。

产业领导者应采取多管齐下的策略，加速技术应用，同时加强供应链冗余和相关人员的协作。首先，他们应优先投资于可重复应用于多种疾病适应症的平台无关型研发，以最大限度地提高科学进步的投资回报并缩短实用化时间。其次，他们应透过认证跨区域的多家契约製造製造商，并选择性地投资于模组化、一次性使用的技术，建立灵活的生产网络，从而实现快速规模化生产并缩短换线时间。第三，他们应在分散的供应环境中扩大产品可及性，在设计配方和包装时充分考虑实际分销限制，并强调热稳定性和简化给药途径。

经过验证的多方面研究途径，结合相关人员访谈、技术文献综述以及供应链和政策分析，能够产生基于现实世界实践的实用见解。

本综合报告采用三角测量调查方法，结合与关键相关人员的对话、技术文献综述以及供应链和政策分析，以确保提供可靠且可操作的见解。报告以与兽医、疫苗研发人员、契约製造和分销通路负责人进行的结构化访谈为主要资讯来源，旨在了解实际情况、未满足的需求和战略意图。此外，报告还查阅了技术文献和监管指导文件，以检验影响疫苗研发和核准的科学趋势、剂量方面的考虑以及最新进展。

简要概述如何将创新、政策转变和实际韧性结合起来，以最大限度地发挥疫苗在保护动物健康和公共安全方面的潜力。

科学创新、贸易政策转变以及区域性疾病压力之间的相互作用，既给动物疫苗生态系统带来了挑战，也带来了机会。平台技术和製剂科学的进步为更有效、更容易取得的疫苗铺平了道路，但这些成就必须辅以对生产柔软性、分销韧性和与监管机构合作的投资。关税政策和地缘政治因素的变化凸显了供应多元化和区域生产能力的战略重要性，而不断变化的终端用户期望则要求产品不仅有效，而且能够在实际兽医环境中切实可行。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 动物疫苗市场：依产品划分

  • 灭活疫苗
  • 减毒活病毒疫苗
  • 药效疫苗
  • 重组疫苗
  • 次单位疫苗

第九章 动物疫苗市场：依动物类型划分

  • 伴侣动物
    • 猫
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 猪

第十章：动物疫苗市场：依疾病类型划分

  • 细菌感染疾病
    • 梭状芽孢桿菌
    • 大肠桿菌
    • 钩端螺旋体病
    • 巴斯德氏菌
  • 霉菌感染疾病
  • 寄生虫感染疾病
    • 体外寄生虫
    • 体内寄生虫
  • 病毒感染疾病
    • 禽流感病毒
    • 牛病毒性腹泻病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 猪繁殖与呼吸综合症病毒（PRRSV）
    • 狂犬病毒

第十一章 动物疫苗市场：依给药途径划分

  • 注射疫苗
    • 肌肉内注射（IM）
    • 静脉注射（IV）
    • 皮下（SC）
  • 口服疫苗

第十二章 动物疫苗市场：依通路划分

  • 网路药房
  • 零售药房
  • 动物医院

第十三章 动物疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 动物疫苗市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 动物疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国动物疫苗市场

第十七章：中国动物疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Biogenesis Bago SA
  • BioVaxys Technology Corporation
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private limited
  • Ceva Sante Animale
  • China Animal Husbandry Industry Co., Ltd.
  • Dalan Animal Health
  • Elanco Animal Health Inc.
  • Endovac Animal Health, LLC by Immvac Inc.
  • Hester Biosciences Limited
  • HIPRA, SA
  • Indian Immunologicals Limited
  • Kemin Industries, Inc.
  • Merck KGaA
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • SAN Vet Holding GmbH
  • Sanofi SA
  • Seppic SA
  • Torigen Pharmaceuticals Inc.
  • Vaxxinova GmbH
  • VEROVACCiNES GmbH
  • Vetigenics, LLC
  • Vetoquinol SA
  • Virbac, Inc.
  • Zoetis Inc.
Product Code: MRR-ED54C46E8F03

The Animal Vaccines Market was valued at USD 14.58 billion in 2025 and is projected to grow to USD 15.53 billion in 2026, with a CAGR of 6.99%, reaching USD 23.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.58 billion
Estimated Year [2026] USD 15.53 billion
Forecast Year [2032] USD 23.40 billion
CAGR (%) 6.99%

A clear, strategic framing of scientific progress, stakeholder pressures, and operational imperatives that redefine priorities for animal vaccine development and deployment

The animal vaccines sector sits at a pivotal junction where scientific innovation, shifting disease dynamics, and evolving stakeholder expectations converge to reshape priorities for manufacturers, veterinarians, and policymakers. Recent advances in molecular biology and immunology have accelerated the development of next-generation modalities, while rising demand for disease prevention across companion animals and livestock has intensified the need for robust vaccine portfolios. Stakeholders face a complex mix of regulatory rigor, ethical considerations around animal welfare, and the commercial imperatives of cost-efficiency and distribution agility. These pressures are compounded by changing trade policies, supply chain vulnerabilities, and heightened scrutiny on antimicrobial stewardship, all of which place vaccine-driven prevention strategies at the center of sustainable animal health programs.

Against this backdrop, organizations must synthesize scientific opportunities with pragmatic delivery models to ensure vaccines reach the animals that need them most. Strategic actors will prioritize translational research that shortens the time from discovery to field deployment, invest in cold-chain and alternative administration routes to improve access, and engage proactively with regulators to de-risk development pathways. In short, the introduction underscores a clear imperative: to transform technical progress into scalable, resilient immunization solutions that align with the operational realities of veterinary care and livestock production.

How platform innovations, digital surveillance, and evolving regulatory expectations are catalyzing a new era of precision, access, and resilience in animal immunization strategies

The landscape of animal vaccines is undergoing transformative shifts driven by scientific breakthroughs, digital-enabled practices, and changing epidemiological pressures. Platform technologies such as mRNA and recombinant approaches are moving from experimental phases into targeted applications, enabling faster antigen design and more precise immune modulation. At the same time, traditional modalities like inactivated and live attenuated vaccines continue to be optimized for safety profiles and thermostability, addressing long-standing distribution challenges. Digital tools-from genomic surveillance to supply chain analytics and telemedicine-are enabling earlier detection of outbreaks and more responsive vaccination campaigns, which in turn alter how manufacturers plan production cycles and distribution.

Clinically, the interplay between zoonotic risk awareness and the intensification of livestock production has intensified demand for vaccines that confer broader protection and longer durability. Regulatory bodies are gradually adapting frameworks to accommodate novel technologies while maintaining rigorous safety standards, prompting proactive engagement by developers to streamline approval paths. Meanwhile, end-users such as veterinarians and producers are demanding vaccines that offer clear returns in terms of herd or companion animal health outcomes, ease of administration, and compatibility with antimicrobial stewardship goals. Together, these forces are reshaping investment priorities, compelling incumbents and new entrants alike to align R&D strategies with scalable manufacturing, improved cold-chain solutions, and integrated data-driven services that amplify vaccine impact.

The cascading operational and strategic consequences of 2025 tariff changes that are reshaping sourcing, manufacturing localization, and distribution resilience across the animal vaccine value chain

United States tariff adjustments enacted in 2025 have created layered effects across the animal vaccine value chain, influencing sourcing strategies, production economics, and global trade flows. Increased duties on select inputs and finished biologics have incentivized manufacturers to reassess supplier footprints and to accelerate near-shoring or regionalization of critical production steps. These shifts are not merely cost-driven; they also reflect a strategic emphasis on controlling supply continuity for sensitive biologic components that underpin vaccine manufacturing, such as adjuvants, vials, and specialized reagents. As a result, organizations are prioritizing dual-sourcing arrangements and qualifying additional contract manufacturing partners to reduce single-point dependencies.

Trade policy changes have also affected distribution planning. Higher cross-border costs have encouraged distributors and veterinary services to optimize inventory strategies, extend product shelf-life through formulation improvements, and explore alternative channels that reduce transit complexity. For exporters, tariff volatility has required more sophisticated pricing and contractual frameworks to maintain competitiveness in key regions, while importers have negotiated long-term supply agreements to mitigate exposure to abrupt tariff swings. Importantly, tariff-induced pressures have heightened interest in domestic capacity building, prompting public-private discussions around incentives for localized vaccine production and workforce development. Collectively, these responses are shaping a more resilient but regionally differentiated production and distribution landscape for animal vaccines.

A comprehensive segmentation framework that aligns product modalities, animal categories, disease targets, administration routes, and distribution channels to inform differentiated development and commercialization approaches

Segmentation reveals distinct development, adoption, and commercialization dynamics that require tailored strategies across product types, target animals, disease categories, administration routes, and distribution pathways. Based on Product, the field includes inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines, each presenting different R&D timelines, manufacturing complexities, and cold-chain dependencies; these differences inform prioritization decisions for pipeline investment and capacity planning. Based on Animal Type, the market spans companion animals and livestock animals, where the Companion Animals category further differentiates into cats and dogs, and the Livestock Animals category further differentiates into cattle, poultry, sheep, and swine; this segmentation underscores that clinical needs, dosing regimens, and distribution models vary substantially between household pets and production animals, driving distinct commercial channels and communication strategies.

Based on Disease Type, attention must be allocated across bacterial infections, fungal infections, parasitic infections, and viral infections. Within bacterial infections, clinical focus areas include clostridial diseases, E. coli, leptospirosis, and pasteurella, while parasitic infections break down into ectoparasites and endoparasites. Viral infections demand specialized responses to agents such as avian influenza virus, bovine viral diarrhea virus (BVDV), foot-and-mouth disease virus (FMDV), Newcastle disease virus, porcine reproductive and respiratory syndrome virus (PRRSV), and rabies virus. Each disease subset drives different antigen design approaches, regulatory pathways, and field efficacy considerations. Based on Route of Administration, vaccines are delivered as injectable vaccines and oral vaccines, with injectable vaccines further categorized by intramuscular, intravenous, and subcutaneous routes; administration route affects compliance, training requirements for administers, and formulation constraints. Based on Distribution Channel, suppliers reach end-users through online pharmacies, retail pharmacies, and veterinary clinics, and each channel imposes unique handling, labeling, and service expectations. Integrating these segmentation lenses enables more precise product positioning, targeted clinical trial designs, and differentiated go-to-market strategies that align with the operational realities of veterinarians and producers.

Distinct regional priorities and infrastructure realities driving differentiated policy, manufacturing, and distribution strategies across the Americas, EMEA, and Asia-Pacific landscapes

Regional dynamics frame distinct strategic priorities for vaccine developers, distributors, and policymakers, reflecting differences in regulatory regimes, production capacity, disease prevalence, and distribution infrastructure. In the Americas, there is a strong focus on regulatory harmonization, cold-chain modernization, and public-private partnerships to address both companion animal and livestock immunization needs. Regulatory agencies in this region emphasize demonstrable safety and efficacy, while industry actors pursue productivity gains through manufacturing automation and precision vaccination programs tied to surveillance data. Cross-border trade within the region supports consolidated production hubs, but recent policy shifts have incentivized greater supply diversification to reduce exposure to external shocks.

Europe, Middle East & Africa presents a mosaic of market conditions where advanced regulatory frameworks in some economies coexist with resource-constrained settings that require low-cost, thermostable formulations and decentralized distribution models. Demand in this region is influenced by strong animal welfare advocacy, stringent pathogen control standards, and a high level of veterinary professionalization in certain markets. Public health priorities drive collaborative initiatives for zoonotic disease prevention, while capacity gaps in parts of Africa and the Middle East create opportunities for novel delivery strategies and local manufacturing ventures.

Asia-Pacific continues to be a strategic focus due to its high livestock densities, diverse production systems, and rapidly modernizing veterinary sectors. Rapid urbanization, intensification of poultry and swine production, and persistent endemic and emerging viral threats place a premium on scalable vaccine solutions and rapid-response platforms. Governments in the region have shown interest in strengthening domestic biotech capabilities and in policies that support vaccine self-sufficiency, which creates an environment conducive to technology transfer, regional contract manufacturing, and collaborative surveillance networks. Across all regions, localized regulatory intelligence, disease profiling, and channel strategies are essential to unlocking adoption and sustaining immunization programs.

Market leaders and agile innovators are forging partnerships, securing specialized manufacturing capacity, and integrating services to convert technological advantage into durable commercial positioning

Competitive dynamics in the animal vaccines space are shaped by a mix of multinational firms, specialized biotech innovators, and contract manufacturers that provide flexible capacity. Established players continue to invest in portfolio diversification and manufacturing resilience, balancing legacy platforms such as inactivated and live attenuated vaccines with emerging technologies like mRNA and recombinant constructs. Specialized biotech entrants are advancing niche indications and platform capabilities, often partnering with contract development and manufacturing organizations to scale production rapidly and to de-risk capital-intensive facility builds. Meanwhile, contract manufacturers and service providers play an increasingly strategic role by offering modular, purpose-built capacity that shortens commercialization timelines and supports regional localization efforts.

Strategic collaborations, licensing agreements, and co-development models have become common, allowing organizations to combine scientific expertise, regulatory know-how, and distribution reach. Intellectual property around novel adjuvants, thermostable formulations, and antigen-display platforms is a critical differentiator, as is the ability to translate genomic surveillance insights into updated vaccine strains. Companies that integrate post-sale services-such as cold-chain monitoring, vaccination adherence platforms, and data analytics-enhance customer value and create stickiness with veterinarians and producers. In sum, the competitive landscape rewards agility in product innovation, manufacturing partnerships, and the ability to deliver end-to-end solutions that reduce operational friction for end-users.

Actionable strategic imperatives for manufacturers and stakeholders to accelerate innovation, diversify production, and strengthen regulatory and commercial partnerships for vaccine resilience

Industry leaders should adopt a multi-pronged strategy that accelerates technological translation while strengthening supply chain redundancy and stakeholder engagement. First, prioritize platform-agnostic R&D investments that can be re-targeted across multiple disease indications to maximize the return on scientific advances and to shorten the time to field deployment. Second, develop flexible manufacturing networks by qualifying multiple contract manufacturers across regions and by investing selectively in modular, single-use technologies that enable rapid scale-up and reduce changeover times. Third, design formulations and packaging with real-world distribution constraints in mind, emphasizing thermostability and simplified administration routes to broaden access in decentralized delivery settings.

Additionally, cultivate closer collaboration with regulatory authorities to pilot adaptive approval pathways for novel modalities and to align on post-approval evidence generation. Strengthen relationships with veterinarians through education, data-driven outcomes measurement, and integrated service offerings that support vaccination adherence and herd-level decision-making. Finally, embed trade-risk mitigation into commercial planning by diversifying supplier bases, negotiating flexible contracting terms, and engaging with policymakers to support incentives for domestic capacity where strategic. Executing on these recommendations will increase resilience, accelerate adoption, and create measurable value for animal health stakeholders across companion and production animal segments.

A validated, multi-source research approach combining stakeholder interviews, technical literature review, and supply chain and policy analysis to produce actionable insights grounded in operational realities

This research synthesis draws on a triangulated methodology combining primary stakeholder engagement, technical literature review, and supply chain and policy analysis to ensure robust, actionable findings. Primary inputs included structured interviews with veterinary clinicians, vaccine developers, contract manufacturers, and distribution channel leaders to capture operational realities, unmet needs, and strategic intent. Technical literature and regulatory guidance documents were reviewed to validate scientific trends, modality-specific considerations, and recent policy developments affecting vaccine development and authorization.

Complementary analysis assessed trade and supply chain implications by examining tariff schedules, public procurement practices, and logistical constraints that influence distribution decisions. Comparative regional assessments were informed by disease surveillance reporting and veterinary infrastructure profiling to contextualize adoption barriers and opportunities. Findings were synthesized through an iterative validation process with subject-matter experts to ensure that recommendations reflect practical feasibility and regulatory realism. Throughout, care was taken to avoid extrapolating into speculative market sizing, instead focusing on structural drivers, operational implications, and decision-useful insights for leaders in the animal vaccines ecosystem.

A concise synthesis of how innovation, policy shifts, and operational resilience must be aligned to realize the full potential of vaccines in protecting animal health and public safety

The convergence of scientific innovation, changing trade policies, and region-specific disease pressures presents both challenges and opportunities for the animal vaccines ecosystem. Advances in platform technologies and formulation science create pathways to more effective and accessible vaccines, yet these gains must be matched by investments in manufacturing flexibility, distribution resilience, and regulatory collaboration. Tariff shifts and geopolitical considerations have underscored the strategic importance of supply diversification and regional capacity, while evolving end-user expectations demand products that are not only efficacious but also practical to deploy in real-world veterinary settings.

Going forward, success will favor organizations that integrate technological agility with operational robustness and stakeholder-centric commercialization strategies. Collaboration across the value chain-from tech developers and contract manufacturers to veterinarians and distributors-will accelerate translational success and enhance impact. By aligning R&D priorities with pragmatic delivery solutions and policy engagement, industry actors can strengthen animal health outcomes, protect food systems, and reduce zoonotic risk in an increasingly interconnected world.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Vaccines Market, by Product

  • 8.1. Inactivated Vaccines
  • 8.2. Live Attenuated Vaccines
  • 8.3. mRNA Vaccines
  • 8.4. Recombinant Vaccines
  • 8.5. Subunit Vaccines

9. Animal Vaccines Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep
    • 9.2.4. Swine

10. Animal Vaccines Market, by Disease Type

  • 10.1. Bacterial Infections
    • 10.1.1. Clostridial
    • 10.1.2. E. Coli
    • 10.1.3. Leptospirosis
    • 10.1.4. Pasteurella
  • 10.2. Fungal Infections
  • 10.3. Parasitic Infections
    • 10.3.1. Ectoparasites
    • 10.3.2. Endoparasites
  • 10.4. Viral Infections
    • 10.4.1. Avian Influenza Virus
    • 10.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 10.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 10.4.4. Newcastle Disease Virus
    • 10.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 10.4.6. Rabies Virus

11. Animal Vaccines Market, by Route of Administration

  • 11.1. Injectable Vaccines
    • 11.1.1. Intramuscular (IM)
    • 11.1.2. Intravenous (IV)
    • 11.1.3. Subcutaneous (SC)
  • 11.2. Oral Vaccines

12. Animal Vaccines Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Animal Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Animal Vaccines Market

17. China Animal Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Biogenesis Bago S.A.
  • 18.6. BioVaxys Technology Corporation
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Brilliant Bio Pharma Private limited
  • 18.9. Ceva Sante Animale
  • 18.10. China Animal Husbandry Industry Co., Ltd.
  • 18.11. Dalan Animal Health
  • 18.12. Elanco Animal Health Inc.
  • 18.13. Endovac Animal Health, LLC by Immvac Inc.
  • 18.14. Hester Biosciences Limited
  • 18.15. HIPRA, S.A.
  • 18.16. Indian Immunologicals Limited
  • 18.17. Kemin Industries, Inc.
  • 18.18. Merck KGaA
  • 18.19. Neogen Corporation
  • 18.20. Phibro Animal Health Corporation
  • 18.21. SAN Vet Holding GmbH
  • 18.22. Sanofi S.A.
  • 18.23. Seppic S.A.
  • 18.24. Torigen Pharmaceuticals Inc.
  • 18.25. Vaxxinova GmbH
  • 18.26. VEROVACCiNES GmbH
  • 18.27. Vetigenics, LLC
  • 18.28. Vetoquinol SA
  • 18.29. Virbac, Inc.
  • 18.30. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANIMAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 272. G7 ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. NATO ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 284. NATO ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. NATO ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)